key: cord-0910344-sbepdi1k authors: Kindwall‐Keller, Tamila L.; Ballen, Karen K. title: Umbilical cord blood: The promise and the uncertainty date: 2020-07-03 journal: Stem Cells Transl Med DOI: 10.1002/sctm.19-0288 sha: 78b951a8c9b77caaf24e6c62a6f341906b15dce4 doc_id: 910344 cord_uid: sbepdi1k Unfortunately, many patients referred for hematopoietic cell transplant will not have a fully matched related donor, and finding matched unrelated donors through the registry may be difficult, especially if the recipient is not of Northern European descent [N Engl J Med 2014;371:339‐348]. Umbilical cord blood (UCB) has been an available graft source for hematopoietic cell transplant for more than 30 years, since the first UCB transplant was performed in the late 1980s [N Engl J Med 1989;321:1174‐1178]. UCB is readily available, has low immunogenicity, and does not require as strict of human leukocyte antigen (HLA) matching compared to other graft sources [N Engl J Med 2004;351:2265‐2275]. According to data from the Center for International Blood and Marrow Transplant Research (CIBMTR), an estimated 500 patients in the US will have received a UCB transplant in 2018. Since 2014, haploidentical transplants have surpassed UCB transplants performed in the United States (CIBMTR Summary Slides, 2018, available at https://www.cibmtr.org). Increased use of haploidentical transplants has brought to light concerns about UCB transplants, including delayed engraftment and graft failure, increased nonrelapse mortality, increased infection risk, and UCB acquisition costs [Lancet Oncol 2010;11:653‐660; Biol Blood Marrow Transplant 2019;1456‐1464]. These concerns will need to be addressed for UCB to remain a viable option as a graft source for hematopoietic cell transplant. Other promising therapeutic benefits for UCB, in addition to hematopoietic cell transplant, is its use in regenerative medicine and immune modulation, which is currently being evaluated in ongoing clinical trials. Increased use of haploidentical transplants has brought to light concerns about UCB, including delayed engraftment and graft failure, increased nonrelapse mortality, and increased infection risk. 4 These concerns will need to be addressed for UCB to remain a viable option as a graft source for hematopoietic cell transplant into the future. 1.1 | ADVANTAGES OF UCB TRANSPLANT 1.2 | Single vs double unit UCB transplant UCB has been an available graft source for hematopoietic cell transplant for more than three decades, since the first UCB transplant was performed in a child with Fanconi's anemia in 1988. 5 Over the decades since the first transplant, UCB transplant has been expanded to adult recipients, in part by using two units of UCB per transplant with similar survival seen in patients with hematologic malignancies (Table 1 ). 3 In a study by Baron et al, single unit UCB transplants can be safely performed in adult recipients as long as there is an adequate total nucleated cell dose ≥2.5 × 10 7 /kg. Neutrophil engraftment, relapse rate, nonrelapse mortality, GVHD survival, and overall survival were comparable to double unit UCB transplant. Recipients who had received a double unit UCB transplant had a trend toward increased grade II to IV acute GVHD by univariate analysis. 6 Cell dose per kilogram body weight should determine whether or not an adult recipient should receive one UCB unit or two for UCB transplant as there is no difference in engraftment, relapse, nonrelapse mortality, or overall survival. 3 American community since only 19% will have a fully matched 8/8 unrelated donor. 2 However, more recently the degree of allelic mismatch at HLA-A, HLA-C, or HLA-DR has been associated with a higher risk of transplant-related mortality (TRM). 9 In a retrospective study of single unit UCB transplant by Eapen et al, grades II to IV acute GVHD were associated with allelic mismatch. Relapse and overall mortality were similar unless mismatched at 4 and 5 alleles, respectively. 10 Choosing UCB units with fewer allelic mismatches for transplant may decrease TRM and acute GVHD. 9,10 A retrospective review performed using CIBMTR registry data evaluated the incidence of acute and chronic GVHD in recipients of single and double unit UCB transplants for acute leukemia. Grade II to IV acute GVHD incidence was 45% and 39% in double and single unit UCB transplants, respectively. The 1-year chronic GVHD incidence was similar between the two groups. 11 Worse HLA match was associated with higher incidence of acute GVHD in both single 10 UCB is associated with increased risk of infectious complications especially in the first 100 days after transplant. 22 Delayed engraftment is a major concern regarding the use of UCB as a graft source for hematopoietic transplant for adults. Studies are ongoing evaluating different ways to improve the time to engraftment in UCB transplant recipients (Table 2 ). Mesenchymal stromal cell coculture, 27, 28 notch-mediated expansion, 29 nicotinamide-associated expansion, [30] [31] [32] aryl hydrocarbon inhibition, 33 In vitro generation of red blood cells may allow production and distribution of red blood cells to augment the national blood supply especially in times of shortages and provide red blood cells for patients with rare blood groups or alloimmunization. 61 Using supplements added to cell culture, in order to avoid animal components, UCB mononuclear cells were able to be differentiated into the erythroid cell lineage. 62 UCB cells stimulated with cytokines and cocultured with UCB mesenchymal stem cells generated clinical quality red blood cells. 63 While generation of red blood cells from UCB cord precursors is exciting, processes are limited by efficiency issues, inability to produce large quantities, and maturing cells to the adult phenotype. 64 These process issues will need to be overcome before UCB red blood cell manufacturing will be able to produce the quantities of red blood cells needed to augment the blood supply. 62 regenerative and immune modulatory properties of UCB for nonhematologic diseases. The authors declared no potential conflicts of interest. K.K.B. and T.L.K.-K. participated in the conception and design as well as writing of the manuscript. Data sharing is not applicable to this article as no new data were created or analyzed in this study. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides HLA match likelihoods for hematopoietic stem-cell grafts in the US registry Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling Single-or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia Better allele-level matching improves transplant-related mortality after double cord blood transplantation Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy GvHD after umbilical cord blood transplantation for acute: leukemia: an analysis of risk factors and effect on outcomes Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation Cord-blood transplantation in patients with minimal residual disease Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia Double unit umbilical cord blood transplantation of hematologic malignancies: a long-term analysis from the SFGM-TC registry One-unit versus two-unit cordblood transplantation for hematologic cancers Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis T cell depletion in paediatric stem cell transplantation Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells Infectious complications after umbilical cord blood transplantation for hematologic malignancy Comparison of graft acquisition and early direct charges of haploidentical related donor transplantation versus umbilical cord blood transplantation Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources Cord-blood engraftment with ex vivo mesenchymal-cell coculture Ex vivo mesenchymal precursor cell-expanded cord blood transplantation after reduced-intensity conditioning regimens improved time to neutrophil recovery Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreased early infection and hospitalization Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation my enhance engraftment Transplantation of ex vivo expanded cord blood cell using the copper chelator tetraethylenepentamine: a phase I/II clinical trial Augmentation of umbilical cord blood transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase I trial Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation Complement fragment 3a priming of umbilical cord blood progenitors, safety profile In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematologic malignancies Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival Mgta-456 cell therapy in inherited metabolic disease (IMD) yields rapid and durable long-term improvement of disease-specific outcomes in a phase 2 trial Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EMBT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLAhaploidentical related bone marrow in advanced hematologic cancer Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation Phenotypic characterization and antitumor effects of cytokine-induced killer cells derived from cord blood Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human Bacute lymphoblastic leukemia cell lines Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors Ex vivo-expanded natural killer cells derived from long-term cryopreserved cord blood are cytotoxic against primary breast cancer cells Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells Banking of pluripotent adult stem cells as an unlimited source for red blood cell production: potential applications for allow immunized patients and rare blood challenges Generation of clinical-grade red blood cells from human umbilical cord blood mononuclear cells In vitro clinical-grade generation of red blood cells from human umbilical cord blood CD34+ cells Ex-vivo generation of human red cells for transfusion Involvement of immune response in the efficacy of cord blood cell therapy for cerebral palsy Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy Allogeneic umbilical cord blood infusion of adults with ischemic stroke. Clinical outcomes from a phase I safety study Phase I-II clinical trial assessing safety and efficacy of umbilical cord blood mononuclear cell transplant therapy of chronic complete spinal cord injury Exosomes derived from Akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D Recent stem cell advances: cord blood and induced pluripotent stem cell for cardiac regeneration-a review How to cite this article: Kindwall-Keller TL, Ballen KK. Umbilical cord blood: The promise and the uncertainty